Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2571 participants.
Also called NCT02831608
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,571 participants
- Registry
-
NCT02831608
-
- Main results
- Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Bangladesh, Czechia, Denmark, Latvia, Norway, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02831608. Randomized; quadruple masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2021-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis
- Acronym
- IAMI
- Condition
- Myocardial Infarction
- Condition
- Influenza, Human
- Condition
- Influenza Vaccines
- Condition
- Heart Failure
- Condition
- Stroke
- Intervention (Biological)
- Influenza vaccine
- Intervention (Biological)
- Placebo
- Lead sponsor
- Ole Frobert, MD, PhD
- Collaborator
- Swedish Heart Lung Foundation
- Collaborator
- Sanofi Pasteur, a Sanofi Company
- Collaborator
- Uppsala University
- Collaborator
- Lytics
Record details
- Record id
cardio:ct-nct02831608- Content hash
8604a3e1228ce288cb0e4d04e286675ecbf488f76f4c7eaa0e3f869eabb89e4d